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Mitotic centromere-associated kinesin (MCAK) is a microtubule (MT) depolymerase necessary for ensuring proper kinetochore MT
attachment during spindle formation. To determine MCAK expression status and its clinicopathological significance, real-time reverse
transcriptase–polymerase chain reaction was used in 65 cases of gastric cancer. MCAK gene expression in cancer tissue was
significantly higher than expression in non-malignant tissue (Po0.05). Elevated MCAK expression was significantly associated with
lymphatic invasion (P¼0.01) and lymph node metastasis (P¼0.04). Furthermore, patients with high MCAK expression had a
significantly poorer survival rate than those with low MCAK expression (P¼0.008). Immunohistochemical study revealed that
expression of MCAK was primarily observed in cancer cells. Additionally, a gastric cancer cell line (AZ521) that stably expressed
MCAK was established and used to investigate the biological effects of the MCAK gene. In vitro results showed that cells transfected
with MCAK had a high rate of proliferation (Po0.001) and increased migratory ability (Po0.001) compared to mock-transfected
cells. This study demonstrated that elevated expression of MCAK may be associated with lymphatic invasion, lymph node metastasis,
and poor prognosis. These characteristics may be due in part to the increased proliferative and migratory ability of cells expressing
MCAK.
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Gastric cancer is the fifth most common malignancy and the second
leading cause of cancer death in the world. Significant geographic
variation exists, with high-risk areas such as Japan, Eastern Asia, and
Central and South America (Terry et al,2 0 0 2 ;S a k a m o t oet al, 2004).
The incidence is relatively low in the United States; however, gastric
cancer is a significant cause of morbidity and mortality, with 23000
cases per year, resulting in 12000 annual deaths (Jemal et al, 2004).
To improve survival rate, development of novel treatments is crucial,
and new molecular targets are desirable.
Mitotic centromere-associated kinesin (MCAK), which is a
member of kinesin-13, is found throughout the cell, and is
especially concentrated at the centromeres, kinetochores, and
spindle poles (Wordeman and Mitchison, 1995). Kinesin family
(KIF) proteins with the kinesin motor catalytic domain and the
coiled-coil domain are microtubule (MT)-dependent molecular
motors (Brady, 1985; Vale et al, 1985; Hirokawa et al, 1989; Endow,
2003). Members of the kinesin superfamily play an important role
in intracellular transport and cell division (Wittmann et al, 2001).
The MT cytoskeleton is a dynamic structure in which the length of
the MTs is tightly regulated. One regulatory mechanism is
depolymerisation of MTs by motor proteins in the kinesin-13
family (Helenius et al, 2006). The human genome has three distinct
genes encoding the following kinesin-13 family members:
Kif2a (chromosome 5q12), Kif2b (chromosome 17q22), and
MCAK/Kif2c (chromosome 1p34). Unlike other kinesins
that transport cargo, MCAK and other kinesin-13 members
catalyse MT disassembly, a key element in normal chromosome
movement (Maney et al, 1998; Helenius et al, 2006). Over-
expression of wild-type MCAK is known to induce depolymerisation
of MTs in both mitotic and interphase cells (Kline-Smith
and Walczak, 2002).
Regarding the association of MCAK with cancer, increased levels
of both MCAK and the Aurora kinases have been reported to be
correlated with tumorigenesis (Perou et al, 1999). Overexpression
of MCAK causes a moderate increase in the frequency of
multipolar spindles (Holmfeldt et al, 2004) and monopolar
spindles (Kline-Smith and Walczak, 2002), which could contribute
to the gain or loss of chromosomes in daughter cells. Mitotic
centromere-associated kinesin mRNA was reported to be highly
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sexpressed in colon cancer tissue (Mori et al, 1993; Scanlan et al,
2002). There have been no reports on the functional analysis of
MCAK expression in human gastric cancer, the second most
common cancer in Japan.
In this study, we examined the clinicopathological and
prognostic significance of MCAK expression in gastric cancers.
We report on the overexpression of MCAK and the association of
MCAK expression with lymphatic invasion, lymph node metas-
tasis, and poor prognosis in gastric cancer.
MATERIALS AND METHODS
Clinical cases
Patients and sample collection Primary gastric cancer specimens
and matched control samples were obtained from 65 patients who
underwent surgery at the Medical Institute of Bioregulation
Hospital, Kyushu University. All specimens were immediately
frozen in liquid nitrogen and stored at  801C until RNA
extraction. Written informed consent was obtained from all
patients. Whenever possible, specimens were also prepared for
immunohistochemical studies. All 65 patients were clearly
identified as having gastric cancer, based on the clinicopathologic
findings. No patients received chemotherapy or radiotherapy
before surgery. All patients were closely followed after surgery at
regular 1-month intervals. The follow-up periods ranged from 2 to
67 months, with a mean of 30 months. All data, including age, sex,
serosal invasion, lymphatic invasion, lymph node metastasis,
vascular invasion, liver metastasis and histology were obtained
from the clinical and pathologic records.
Total RNA extraction Frozen tissue specimens were homo-
genised in guanidium thiocyanate, and total RNA was obtained
by ultracentrifugation through a cesium chloride cushion, as
described previously (Mori et al, 1993).
Evaluation of MCAK expression in clinical samples As described
previously, cDNA was synthesised from 8.0mg of total RNA (Inoue
et al, 1995). The glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene served as an internal control. Two gene-specific
oligonucleotide primers were designed: (MCAK) sense, 50-GATGG
AAGCCTGCTCTAACG-30; antisense, 50-GAGCAGATTCCGCTTTG
TTC-30;( GAPDH) sense, 50-TTGGTATCGTGGAAGGACTCA-30;
antisense, 50-TGTCATCATATTTGGCAGGTT-30. The following
temperature profile was used: initial denaturation at 951C for
10min, followed by 40 cycles of denaturation at 951C for 10s,
annealing at 661C (601C for GAPDH) for 10s, and extension at
721C for 10s. PCRs were performed in a LightCyclerTM system
(Roche Applied Science, Indianapolis, IN, USA) using the Light-
Cycler FastStart DNA Master SYBR Green I Kit (Roche Applied
Science), as described previously (Ogawa et al, 2004). All
concentrations were calculated relative to the concentration of
the cDNA from Human Universal Reference total RNA (Clontech,
Mountain View, CA, USA), and the concentration of MCAK was
then divided by the concentration of endogenous reference
(GAPDH) to obtain normalised expression values (Bieche et al,
1998a,b, 1999). Each assay was performed three times to verify the
results, and the mean normalised value of mRNA expression was
used for subsequent analysis.
Immunohistochemistry Immunohistochemical studies of surgical
specimens for MCAK expression were performed on formalin-
fixed, paraffin-embedded tissues from gastric cancer patients.
After deparaffinisation and blocking of tissue sections, primary
goat polyclonal antibody against MCAK (Abcam, Cambridge, UK)
was applied at a 1:100 dilution, and the antigen–antibody reaction
was incubated overnight at 41C. ENVISION reagents (ENVI-
SIONþDual Link/HRP; Dako Cytomation, Glostrup, Denmark)
were used to detect the antigen–antibody reaction. All tissue
sections were counterstained with haematoxylin.
Experimental studies
Cell lines The cell lines derived from human gastric cancer cell
AZ521, KATO3, MKN1, MKN7, MKN28, MKN45, MKN74, NUGC3,
NUGC4, SH10TC, and the human fibrosarcoma cell HT1080 were
obtained from the Cell Resource Center for Biomedical Research
Institute of Development, Aging and Cancer (Tohoku University,
Sendai, Japan) and maintained in RPMI-1640 medium containing
10% (vv
 1) fetal bovine serum (FBS) and antibiotics at 371Ci na
5% humidified CO2 atmosphere.
DNA transfection The MCAK gene expression vector (EGFP-
HsMCAK) was a generous gift from Professor Linda Wordeman
(University of Washington School of Medicine, Seattle, WA, USA)
(Moore and Wordeman, 2004). To confirm accurate insertion into
the frame of the expression vector, sequencing chemistry was
performed. AZ521, a gastric cancer cell line, did not express MCAK
mRNA among 10 gastric cancer cell lines (data not shown).
Therefore, AZ521 was used for the transfection assays. The
FuGENE 6 (cat. # 1815091; Roche Applied Science) transfection
reagent was employed to establish permanently transfected cells,
which were then selected by treatment with the antibiotic G418
(Invitrogen, Carlsbad, CA, USA) to the specific clone for in vitro
assays, as described previously (Adrain et al, 1999).
Western blot analysis Western blotting and immunocytochemical
staining were used to confirm the expression of MCAK in the
EGFP-HsMCAK- and mock-transfected cells. Total protein was
extracted from samples using PRO-PREP protein extraction
solution (iNtRON Biotechnology Inc., Kyungi-Do, Korea). Aliquots
of total protein were applied to 10% acrylamide gradient gels. After
electrophoresis, the samples were electroblotted (0.2A, 120min,
41C) onto a polyvinylidene membrane (Immobilon; Millipore Inc.,
Bedford, MA, USA). The MCAK protein was detected with goat
polyclonal antibody at a 1:250 dilution. The protein levels of
MCAK were normalised to the level of b-actin protein, which was
detected by a 1:1000 dilution of anti-b-actin antibody (Cytoskel-
ton Inc., Denver, CO, USA). The blots were developed using
horseradish peroxidase-conjugated anti-goat immunoglobulin
(Promega Inc., Madison, WI, USA) at a dilution of 1:5000. Signals
were detected using SuperSignal (Pierce Biotechnology Inc.,
Rockford, IL, USA).
In vitro assays The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) assay (Roche Diagnostics Corp. GmbH,
Mannheim, Germany) was used to determine cell proliferation.
Logarithmically growing MCAK- and mock-transfected AZ521
cells were seeded at 5.0 10
3cellswell
 1 in 96-well flat-bottomed
microtitre plates, in a final volume of 100ml culture medium per
well, and incubated in a humidified atmosphere (371C and 5%
CO2). After incubation, 10ml of MTT labeling reagent (final
concentration 0.5mgml
 1) was added to each well, and the plate
was incubated for 4h in a humidified atmosphere. Solubilisation
solution (100ml) was added to each well, and the plate was
incubated overnight in a humidified atmosphere. After confirma-
tion that the purple formazan crystals were completely solubilised,
the absorbance of each well was measured by a Model 550 series
microplate reader (Bio-Rad Laboratories, Hercules, CA, USA), at a
wavelength of 570nm corrected to 655nm. Each independent
experiment was performed three times.
For cell cycle analysis, MCAK- and mock-transfected AZ521
cells (2.0 10
6) were preincubated for 24h in 10ml of serum-free
medium at 371C, and were then incubated in medium containing
10% FBS (vv
 1) for an additional 18h at 371C. The cells were
harvested and fixed in 70% ethanol at  201C, and then washed and
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sresuspended in propidium iodide (PI) (BD Biosciences, San Jose,
CA, USA) staining buffer containing 5mg PI and 0.25mg RNase per
millilitre PBS. DNA content was measured with an EPICS XL flow
cytometer (Beckman Coulter Corp., Tokyo, Japan).
Migration assays were performed using BD Falcon FluoroBlock
8mm HTS Cell Culture Inserts for 24-well plates (cat. # 351152; BD
Biosciences) to evaluate invasive cells, as described previously
(Albini et al, 1987). Briefly, cells (5.0 10
4cells per 0.5ml per well)
were placed in the upper chamber, and the lower chamber was
filled with 750ml DMEM with 10% (vv
 1) fetal calf serum as a
chemoattractant. After 24, 36, and 48h of incubation at 371C,
insert membranes were labeled with calcein-AM reagent (Mole-
cular Probes, Carlsbad, CA, USA). Migrating cells that had passed
through the membrane to its lower surface were evaluated in a
fluorescence plate reader (Perkin-Elmer, Waltham, MA, USA) at
excitation/emission wavelengths of 485/530nm. Migratory ability
was calculated from the ratio of fluorescence of the MCAK- or
mock-transfected AZ521 cells to the fluorescence of the invasive
cells of HT1080, the human fibrosarcoma cell line that served as a
control.
Anoikis assays were performed in six-well Costar Ultra Low
Attachment Microplates (cat. # 3471; Corning Inc., Corning, NY,
USA). Mitotic centromere-associated kinesin- or mock transfected
AZ521 cells were suspended in RPMI-1640 with 10% FBS at a level
of 0.5 10
6cellsml
 1, and 2ml of cell suspension was added to
each well and incubated in the microplates for 18h in a humidified
(371C and 5% CO2) incubator. Following the induction of anoikis,
the cells were washed and resuspended in 0.5ml of binding buffer,
and annexin V:fluorescein isothiocyanate/PI labeling was per-
formed in accordance with the manufacturer’s protocol (BD
Biosciences). Analysis was performed by FACScan (BD Bio-
sciences). Each sample contained 1 10
4cells. The data were
analysed by CellQuest software (BD Biosciences). These proce-
dures were also performed in triplicate.
Statistical analysis
Quantitative real-time reverse transcriptase–polymerase chain
reaction (RT–PCR) data and in vitro transfected cell assay data
were analysed by JMP 5 for Windows software (SAS Institute Inc.,
Cary, NC, USA). Patient’s overall survival rates were calculated
actuarially according to the Kaplan–Meier method (Kaplan and
Meier, 1958) and were measured from the day of surgery.
Differences between groups were estimated using the w
2 test,
Student’s t-test, repeated-measures ANOVA test, and the log-rank
test (Mantel, 1966). Variables with a value of Po0.1 in univariate
analysis were used in a subsequent multivariate analysis based on
the Cox proportional hazards model. A probability level of 0.05
was chosen for statistical significance.
RESULTS
Clinical cases
Mitotic centromere-associated kinesin expression in clinical samples
Reverse transcriptase–polymerase chain reaction analysis of four
representative clinical tissue samples demonstrated unequivocal
MCAK mRNA expression in cancer samples compared with
negative expression in the paired samples of adjacent normal
tissue (Figure 1A). To investigate the high level of MCAK
expression in the initial cancer samples, all 65 paired clinical
samples of gastric cancers were then submitted for quantitative
real-time RT–PCR analysis. There were 43 of 65 patients (66.2%)
with a higher expression level of MCAK mRNA in gastric cancer
A
B
MK18 MK22 MK137 MK154
NC PC m NTNTNTNT
MCAK
GAPDH
100 m
100 m 500 m
Figure 1 Mitotic centromere-associated kinesin mRNA expression in clinical samples. (A) RT–PCR analysis of MCAK in gastric cancer (T) and paired
normal (N) samples obtained from four patients (patient numbers: MK 18, 22, 137, and 154). Mitotic centromere-associated kinesin mRNA expression was
observed in cancer samples, but no expression was seen in normal samples. GAPDH was used as a control. m¼marker; NC¼negative control;
PC¼positive control. (B) Immunohistochemistry of gastric cancer surgical specimens using an antibody to MCAK. Positive staining was observed in cancer
cells, but not in normal mucosal epithelium (magnification  40 (left image)). A dotted circle indicates normal mucosa and a solid line circle indicates cancer
cells. In normal mucosa (right upper image, magnification  100), solid line arrows indicate proliferating cells of the glandular neck and dotted line arrows
indicate macrophages.
MCAK in gastric cancer
Y Nakamura et al
545
British Journal of Cancer (2007) 97(4), 543–549 & 2007 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
stissues than in non-malignant tissues. The mean expression value
of MCAK mRNA in cancer tissues was 0.2570.015 (mean7s.d.,
normalised by GAPDH gene expression), which was significantly
higher than the value of 0.1870.025 in the corresponding non-
malignant tissues (P¼0.0145; Student’s t-test). Figure 1B shows
the immunohistochemical result of a representative clinical sample
from a gastric cancer patient. Most of the staining is seen in the
cytoplasm of cancer cells, proliferating cells of glandular neck, and
macrophage, and not in stromal cells or normal epithelium. Thus,
proliferating cells demonstrated high MCAK expression.
Clinicopathologic and prognostic analyses of gastric cancers In
the current study, patients with less than the median MCAK mRNA
expression ratio of cancerous to normal tissue (T/N) were assigned
to the low-expression group (n¼33), and the others were assigned
to the high-expression group (n¼32). Table 1 shows the
clinicopathologic data and MCAK mRNA expression ratio of
cancerous to normal tissue (T/N) from the 65 gastric cancer
patients. The incidences of lymph node metastasis (P¼0.04) and
lymphatic invasion (P¼0.01) were significantly higher in the high-
expression group than in the low-expression group. There were no
significant differences seen between the other observed clinico-
pathological factors that were compared between the two
expression groups. Moreover, the 5-year actuarial overall survival
rates in patients with a high MCAK expression ratio and patients
with a low MCAK expression ratio were 45 and 79%, respectively
(Figure 2). The survival difference between these two groups was
statistically significant (P¼0.008). Multivariate analysis indicated
that the median expression ratio of MCAK was found to be an
independent and significant prognostic factor for survival (OR,
1.95; CI, 1.21–3.36) (Table 2).
Experimental studies
In vitro proliferation and cell cycle assays To estimate whether
high MCAK expression affects cell growth rates, the MCAK gene
was transfected into the gastric cancer cell line AZ521 (Figure 3A),
and a proliferation assay was performed. As shown in Figure 3B,
there was a significant difference in the growth rate between the
MCAK- and the mock-transfected cells (Po0.001). Between
original cells and mock-transduced cells, there was no significant
difference in the proliferation assays (data not shown). To
investigate whether the MCAK-transfected cells showed high
proliferative activity, the cell cycle was analysed. The percentage
of cells in G1-, S-, and G2þM phase of MCAK-transfected cells
were 44.574.62, 40.9711.9, and 6.4375.83, respectively. On the
other hand, the percentage of cells in G1-, S-, and G2þM phase of
mock-transfected cells were 65.572.68, 16.374.71, and 17.178.87,
respectively. The percentage of cells in S phase of MCAK-
transfected cells was higher than the percentage of mock-
transfected cells in S phase, following treatment with serum
starvation for 24h and serum refeeding for 18h (Figure 3C). These
results suggest the possibility that MCKA gene expression would
be associated with cell proliferation because of increased cell
cycling in gastric cancer cells.
In vitro migration and anoikis assays Whether MCAK expression
would alter the migratory ability of AZ521 gastric cancer cells was
Table 1 Relationship between MCAK status and other variables
MCAK expression (T/N)
High
a (%) Low
a (%) P-values*
Number of tumours 32 33 —
Average age
a (years) 64.672.4 65.172.3 0.87
Sex
Female 9 (28.1) 14 (42.4)
Male 23 (71.9) 19 (57.6) 0.23
Serosal invasion
+ 12 (37.5) 11 (33.3)
  20 (62.5) 22 (66.7) 0.73
Lymphatic invasion
+ 26 (81.3) 17 (51.5)
  6 (18.8) 16 (48.5) 0.01
Lymph node metastasis
+ 24 (75.0) 16 (48.5)
  8 (25.0) 16 (48.5) 0.04
Vascular invasion
+ 9 (28.1) 4 (12.1)
  23 (71.9) 29 (87.9) 0.10
Liver metastasis
+ 9 (28.1) 1 (3.0)
  23 (71.9) 32 (97.0) 0.28
Histology
b
Well 1 (3.1) 4 (12.1)
Mod. 12 (37.5) 6 (18.2)
Poor 9 (28.1) 13 (39.4) 0.10
MCAK¼mitotic centromere-associated kinesin; T/N¼ratio of cancerous to normal
tissue.
aHigh and low: a group of patients with the higher and the lower T/N
expression of MCAK than the median T/N level, respectively.
bWell, well-
differentiated adenocarcinoma; mod., moderately differentiated adenocarcinoma;
poor, poorly differentiated adenocarcinoma. *Correlation was analysed by the w
2
method. Statistical significance between patients of MCAK high and low was
observed in the incidence of lymphatic permeation (0.01) as well as lymph node
metastasis (0.04).
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Figure 2 Overall survival rate of patients with gastric cancer grouped
according to MCAK mRNA expression status of the tumour. Patients with
high MCAK mRNA expression (n¼32) had a significantly poorer prognosis
than those with low MCAK mRNA expression (n¼33).
Table 2 Multivariate analysis for overall survival
Variables Odds ratio 95% CI P-values
Lymph node metastasis 4.18 (1.87–17.86) o0.001
z
Vascular invasion 0.98 (0.60–1.53) 0.947
Serosal invasion 1.54 (1.02–2.33) 0.039
z
MCAK expression
a 1.95 (1.21–3.36) 0.006
z
CI¼confidence interval; MCAK¼mitotic centromere-associated kinesin.
aThe
hazard ratio of the higher MCAK expression compared to the lower expression
for cancer death.
zPo0.05 indicates an independent and significant prognostic factor
for overall survival.
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sassessed in a migration assay in the condition of 24, 36, and 48h.
In all conditions, transfectants demonstrated greater motility than
mock transfectants (Po0.001) (Figure 3D). This result corre-
sponds to the results seen in analysed gastric cancer specimens
that showed significant correlation between MCAK expression and
invasiveness.
Anoikis is associated with cellular migration and metastatic
potential. After anoikis-induced cell culture, more mock-trans-
fected cells (91.73%) were apoptotic than MCAK-overexpressing
cells (78.52%). MCAK-overexpressing cells appeared to be more
resistant to anoikis induction than mock-transfected cells
(Figure 3E). This anoikis assay was performed three times, and
all assays revealed same results.
DISCUSSION
Microtubules, vital components of the cytoskeleton, play impor-
tant roles in mitosis, cell migration, cell signaling, and trafficking
(Honore et al, 2005). Identification of proteins regulating the MT
network of cancer cells could lead to a better understanding of
regulation of tumour progression and will be helpful in improving
cancer therapy. Therefore, we have investigated MCAK, which
controls MT dynamics.
To clarify the aggressive behaviour of tumours with MCAK
overexpression, we used in vitro assays to analyse the function of
MCAK in cancer cells. Gastric cancer cells transfected with MCAK
demonstrated higher migratory rates and greater resistance to
anoikis than mock-transfected cells. It was reported that knock-
down of KIF2A, which has a similar function to MCAK as an MT
depolymerase, results in loss of motility in nerve cells (Homma
et al, 2003). Thus, Kin1 kinesins, such as KIF2A and MCAK, may
regulate cell motility. The results of cell motility experiments may
partly explain our finding that gastric cancer patients with
tumours that express high levels of MCAK had higher rates of
lymphatic invasion and metastasis, and a poorer prognosis.
The regulators of MT dynamics are important for control of
chromosome movement and mitosis (Gigant et al, 2000; Howell
et al, 2001; Ichihara et al, 2001). As for these regulators in cancer
cells, the catastrophe factors of MTs such as oncoprotein (Op)18/
stathmin were reported to be overexpressed in a number of human
malignancies, and to be associated with cancer progression and
prognosis (Roos et al, 1993; Bieche et al, 1998a,b; Brattsand, 2000;
Chen et al, 2003; Moore and Wordeman, 2004; Kouzu et al, 2006).
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Figure 3 Experimental studies. (A) Western blotting revealed that MCAK protein was detected in transfectants but not in mock-transfected cells. b-Actin
was used as a control. Right and left lanes show transfected and mock-transfected cells (cell line AZ521), respectively. (B) Growth rate of MCAK
transfectants and mock-transfected cells in 10% FBS. Bar¼s.d.; cell counts were greater in MCAK transfectants than in mock-transfected cells (Po0.001).
(C) Cell cycle analysis of MCAK transfectants and mock-transfected cells after 24h of serum starvation followed by 18h serum feeding with 10% FBS. The
G1-phase cell counts were unified. The S-phase fraction was greater in transfectants (44.3%) than mock-transfected cells (25.3%). (D) Migration assay. The
migratory ability of transfectants was significantly stronger than that of mock-transfected cells (Po0.001). (E) Anoikis analysis. After anoikis induction for 18h,
the apoptosis rate was measured by annexin V and PI staining. Proportion of apoptotic MCAK-transfected cells (78.52%) was less than that of apoptotic
mock-transfected cells (91.73%).
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sOp18/stathmin is involved in the cell cycle and contributes to
tumorigenesis and proliferation. Suppression of Op18/stathmin
expression interferes with cell cycle progression (Melhem et al, 1991;
Jeha et al, 1996; Mistry and Atweh, 2002). The present study has
revealed that cancer cells overexpressing MCAK, also a regulator of
MT dynamics, showed high proliferative ability compared with
mock-transfected cells. In addition, cell cycles of MCAK-expressing
cells were faster than cell cycles of mock-transfected cells. These
results may also contribute to the explanation of the aggressive
behaviour of MCAK-overexpressing tumours.
MCAK has potential as a therapeutic target. The sulfoquinovo-
sylacylglycerols (SQAGs) found in ferns and algae were reported as
novel anticancer agents that inhibit DNA polymerase (Ohta et al,
2001). Recently, Aoki et al (2005) reported that the target of SQAGs
was not only DNA polymerase, but also MCAK. Some SQAGs
studies have demonstrated good antitumour effects (Sahara et al,
1997; Matsumoto et al, 2002). These results, combined with our
findings, suggest that this novel anticancer agent may be effective
in gastric cancer patients with tumours that overexpress MCAK.
In normal human organs, MCAK gene expression is distributed
only in the testis (Scanlan et al, 2002). Our pilot study illustrated
the same result (data not shown). From SAGE analysis
(www.cgap.gov), MCAK was found to be highly expressed in testis
and ovaries, which contain meiotic cells and a high number of
proliferating cells. Mitotic centromere-associated kinesin is
expressed in other tissue types at levels considered negligible.
This suggests that MCAK could be a cancer testis antigen (CTA)
and could become an immunotherapy target antigen. Immuno-
therapy, which uses tumour-specific peptides, RNA, or tumour
lysate, is now considered one of the therapeutic strategies against
advanced cancer (Gilboa et al, 1998; Sadanaga et al, 2001; Shimizu
et al, 2001). We previously reported on the expression of MAGE-1
and MAGE-3 in several cancers (Inoue et al, 1995), and we
identified several MAGE peptides that are recognised by cytotoxic
T lymphocytes (Tanaka et al, 1997; Fujie et al, 1999). On the basis
of these findings, cancer-specific immunotherapy using the HLA
class I restricted MAGE peptide has been used in our institution
for patients with advanced cancers (Sadanaga et al, 2001).
However, MAGE expression is restricted, and almost less than
half of the tumours studied express MAGE. Thus, a novel CTA
useful for immunotherapy is strongly recommended. We think
that MCAK may be a candidate gene for cancer-specific
immunotherapy.
It has also been reported that MCAK protein was detected from
the blood of colon cancer patients by the SELEX method (Scanlan
et al, 2002), suggesting that MCAK might be useful in diagnosis.
We are now investigating whether the level of MCAK in the blood
correlates with tumour progression or prognosis.
In summary, we confirmed that MCAK is a cancer-specific gene
and that gastric tumours with MCAK expression were associated
with lymphatic invasion, lymph node metastasis, and poor
prognosis. Mitotic centromere-associated kinesin may become a
molecular target of an anticancer drug or cancer-specific
immunotherapy.
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